{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:57Z","timestamp":1793325717342,"version":"4.5.0"},"reference-count":30,"publisher":"Centers for Disease Control MMWR Office","issue":"50","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6950a6","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T19:55:16Z","timestamp":1608234916000},"page":"1911-1916","source":"Crossref","is-referenced-by-count":402,"title":["Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020"],"prefix":"10.15585","volume":"69","author":[{"given":"Sancta","family":"St. Cyr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindley","family":"Barbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Workowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cau","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Schlanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Torrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen N.","family":"Kersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R1","unstructured":"CDC. Sexually transmitted disease surveillance 2018. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https:\/\/www.cdc.gov\/std\/stats18\/STDSurveillance2018-full-report.pdf"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/sti.75.1.3","article-title":"From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection.","volume":"75","author":"Fleming","year":"1999","journal-title":"Sex Transm Infect"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R3","unstructured":"CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R4","article-title":"Sexually transmitted diseases treatment guidelines, 2010.","volume":"59","author":"Workowski","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R5","article-title":"Sexually transmitted diseases treatment guidelines, 2015.","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R6","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections.","volume":"56","author":"CDC","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R7","first-page":"590","article-title":"Update to CDC\u2019s Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R8","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. https:\/\/clsi.org\/media\/3481\/m100ed30_sample.pdf"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R9","first-page":"798","article-title":"Rationale for a Neisseria gonorrhoeae susceptible-only interpretive breakpoint for azithromycin.","volume":"70","author":"Kersh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","article-title":"Macrolide and nonmacrolide resistance with mass azithromycin distribution.","volume":"383","author":"Doan","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMc1901535","article-title":"Macrolide resistance in MORDOR I\u2014a cluster-randomized trial in Niger.","volume":"380","author":"Doan","year":"2019","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R12","doi-asserted-by":"crossref","unstructured":"Bachmann LH, Kirkcaldy RD, Geisler WM, Prevalence ofMycoplasma genitaliuminfection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis 2020;ciaa293. Epub March 18, 2020.","DOI":"10.1093\/cid\/ciaa293"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R13","doi-asserted-by":"crossref","first-page":"e01679","DOI":"10.1128\/AAC.01679-18","article-title":"Genetic mechanisms behind the spread of reduced susceptibility to azithromycin in Shigella strains isolated from men who have sex with men in Qu\u00e9bec, Canada.","volume":"63","author":"Yousfi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R14","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3201\/eid2209.151695","article-title":"Multidrug-resistant Campylobacter coli in men who have sex with men, Quebec, Canada, 2015.","volume":"22","author":"Gaudreau","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/cid\/ciu220","article-title":"Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials.","volume":"59","author":"Kong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R16","doi-asserted-by":"crossref","unstructured":"Dombrowski JC, Wierzbicki MR, Newman L, A randomized trial of azithromycin vs. doxycycline for the treatment of rectal chlamydia in men who have sex with men. Presented at the National STD Prevention Conference, Atlanta, GA: September 14\u201324, 2020.","DOI":"10.1093\/cid\/ciab153"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2165\/00003088-200140090-00004","article-title":"Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.","volume":"40","author":"Perry","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R18","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dkq289","article-title":"Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?","volume":"65","author":"Chisholm","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R19","doi-asserted-by":"publisher","first-page":"e01644","DOI":"10.1128\/AAC.01644-18","article-title":"Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model.","volume":"63","author":"Connolly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-9496-0_3","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea.","volume":"1997","author":"Unemo","year":"2019","journal-title":"Methods Mol Biol"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1542\/peds.2004-2294","article-title":"Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.","volume":"116","author":"Blumer","year":"2005","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R22","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections.","volume":"20","author":"Moran","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/infdis\/jiw420","article-title":"Genomic epidemiology of gonococcal resistance to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in the United States, 2000\u20132013.","volume":"214","author":"Grad","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/cid\/cix249","article-title":"Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin.","volume":"65","author":"Wind","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R25","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2666-5247(20)30059-8","article-title":"Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data.","volume":"1","author":"Gernert","year":"2020","journal-title":"Lancet Microbe"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00007435-199501000-00007","article-title":"Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?","volume":"22","author":"Moran","year":"1995","journal-title":"Sex Transm Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/OLQ.0000000000000033","article-title":"Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada.","volume":"40","author":"Gratrix","year":"2013","journal-title":"Sex Transm Dis"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/sti.2006.024059","article-title":"Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting.","volume":"83","author":"Fung","year":"2007","journal-title":"Sex Transm Infect"},{"key":"key-10.15585\/mmwr.mm6950a6-202012171410-R30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/OLQ.0b013e3181a2a933","article-title":"Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature.","volume":"36","author":"Hosenfeld","year":"2009","journal-title":"Sex Transm Dis"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:40:53Z","timestamp":1670312453000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6950a6.htm?s_cid=mm6950a6_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":30,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020,12,18]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6950a6","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,18]]},"published":{"date-parts":[[2020,12,18]]}}}